Drug intelligence / Profile preview

NNC5840

Development stage: Preclinical
Lead developer: Novo Nordisk
Modality: Peptides
Administration: Subcutaneous

Overview

NNC5840 is a protracted glucagon-like peptide 1 (GLP-1) analogue designed to optimize cAMP-biased signaling at the GLP-1 receptor. In preclinical studies, it has demonstrated a partial-Gsα, cAMP-biased GLP-1R signaling profile in vitro, leading to superior maximal body weight reduction compared to semaglutide in diet-induced obese mice. Its weight loss profile is characterized by reduced in vivo potency but increased maximal efficacy, suggesting a novel approach to obesity pharmacotherapy.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on NNC5840.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC5840.

Explore the full profile